Erratum: Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial (European Journal of Nuclear Medicine and Molecular Imaging (2005) 32 (294-301) DOI: http://dx.doi.org/10.1007/s00259-004-1566-1);Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 3, 2005, Pages 294-301

  Krak, Nanda C ^a   Boellaard, R ^a   Hoekstra, Otto S ^a   Twisk, Jos W R ^a   Hoekstra, Corneline J ^b   Lammertsma, Adriaan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TRACER;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; GEOMETRY; HUMAN; IMAGING SYSTEM; MALE; OUTCOMES RESEARCH; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

EID: 17644421807     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1926-5     Document Type: Erratum

References (35)

1. 18F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med 2002;43:510-8
2. Avril N, Bense S, Ziegler SI, et al. Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nucl Med 1997;38:1186-91
3. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676-88
4. Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology 1999;213:521-5
5. 18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689-95
6. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464-71
7. Choi NC, Fischman AJ, Niemierko A, et al. Dose-response relationship between probability of pathologic tumour control and glucose metabolic rate measured with FDG PET after pre-operative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;54:1024-35
8. Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002;24:127-35
9. Weber WA, Ziegler SI, Thodtmann R, et al. Reproducibility of metabolic measurements in malignant tumours using FDG PET. J Nucl Med 1999;40:1771-7
10. Lee JR, Madsen MT, Bushnel D, et al. A threshold method to improve standardized uptake value reproducibility. Nucl Med Commun 2000;21:685-90
11. Graham MM, Peterson LM, Hayward RM. Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol 2000;7:647-55
12. Hunter GJ, Hamberg LM, Alpert NM, et al. Simplified measurement of deoxyglucose utilization rate. J Nucl Med 1996;37:950-5
13. 11C]tyrosine PET. J Nucl Med 1997;38:692-6
14. Avril N, Dose J, Janicke F, et al. Metabolic characterization of breast tumours with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996;14:1848-57
15. 18F]fluoro-D-glucose. Mol Imaging Biol 2002;4:171-8
16. 18F]fluoro-D-glucose with positron emission tomography: clinical significance of iterative reconstruction and segmented attenuation compared with conventional filtered back projection and measured attenuation correction. Mol Imaging Biol 2002;4:294-300
17. 18F]FDG PET. Eur J Nucl Med 2001;28:1326-35
18. Boellaard R, Krak NC, Hoekstra OS, et al. Effects of noise, image resolution and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004;45:1519-27
19. 18F-FDG PET. J Nucl Med 2002;43:1304-09
20. Boellaard R, van Lingen A, Lammertsma AA. Experimental and clinical evaluation of iterative reconstruction (OSEM) in dynamic PET: quantitative characteristics and effects on kinetic modeling. J Nucl Med 2001;42:808-17
21. 18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 2000;27:731-43
22. Yang SN, Liang JA, Lin FJ, et al. Differentiating benign and malignant pulmonary lesions with FDG-PET. Anticancer Res 2001;21:4153-57
23. Hubner KF, Buonocore E, Gould HR, et al. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images. Clin Nucl Med 1996;21:941-9
24. Minn H, Zasadny KR, Quint LE, et al. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 1995;196:167-73
25. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumours using FDG PET. J Nucl Med 1999;40:1771-7
26. Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-11
27. Mankoff DA, Dunwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003;44:1806-14
28. Jansson T, Westlin JE, Ahlstrom H, et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995;13:1470-7
29. Zasadny KR, Kison PV, Fransis IR, et al. FDG-PET determination of metabolically active tumour volume and comparison with CT. Clin Pos Imaging 1998;1:123-9
30. Erdi YE, Mawlawi O, Larson SM, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer 1997;15:2505-9
31. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-82
32. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995;36:1836-9
33. Ramos CD, Erdi YE, Gonen M, et al. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med 2001;28:155-64
34. 18F-FDG PET. Q J Nucl Med 2002;46:122-30
35. Lonneux M, Borbath I, Bol A, et al. Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction. Eur J Nucl Med 1999;26:591-8